文献速递帕金森病与运动障碍神经免疫

硫唑嘌呤治疗早期帕金森病的随机双盲安慰剂对照2期概念验证试验

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
PubMed 文献 · Lancet Neurol · 2026-01-01

该单中心随机双盲安慰剂对照2期试验纳入66例早期帕金森病患者,评估硫唑嘌呤2 mg/kg/日治疗12个月的疗效。硫唑嘌呤耐受性良好,探索性分析提示对免疫标志物和运动症状可能有影响。

要点

  • 硫唑嘌呤未达到改善早期帕金森病步态-轴向评分的主要终点。
  • 硫唑嘌呤在该人群中耐受性良好,感染和胃肠道不良事件最常见。
  • 探索性分析提示硫唑嘌呤可能影响外周和中枢免疫标志物及运动症状。

核心结论

  • 硫唑嘌呤在早期帕金森病患者中耐受性良好,但主要结局未达到。
  • 探索性分析提示硫唑嘌呤对外周和中枢免疫生物标志物及运动症状有影响。
  • 潜在临床效应在女性中可能大于男性,值得进一步探索。

研究设计与样本

  • 随机、双盲、安慰剂对照、概念验证、2期试验,在英國剑桥单中心进行。
  • 纳入年龄50-80岁、诊断帕金森病3年内的患者,按1:1随机分配至每日口服硫唑嘌呤2 mg/kg或安慰剂,治疗12个月。
  • 共筛查78例,随机分配66例(硫唑嘌呤组32例,安慰剂组34例),均纳入意向性治疗分析。
  • 主要结局为12个月时关期MDS-UPDRS步态-轴向评分较基线的变化。
  • 安全性在所有筛查参与者中评估。

主要发现

  • 硫唑嘌呤组报告159例不良事件,安慰剂组156例。
  • 硫唑嘌呤组8例(24%)发生严重不良事件,安慰剂组4例(12%)。
  • 最常见不良事件为感染(硫唑嘌呤组20/33例[61%] vs 安慰剂组26/34例[76%])和胃肠道疾病(19例[58%] vs 17例[50%])。

临床怎么用

  • 当前证据不支持硫唑嘌呤用于改善早期帕金森病步态-轴向症状的常规治疗。
  • 硫唑嘌呤在该人群耐受性良好,但需监测感染和胃肠道不良事件。
  • 探索性提示的免疫标志物和运动症状效应需进一步研究验证。

局限性

  • 单中心、样本量较小的2期概念验证试验。
  • 主要结局为步态-轴向评分,可能未全面反映疾病进展。
  • 探索性分析结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The immune system is implicated in Parkinson's disease aetiology and prognosis. Although there are effective symptomatic treatments for Parkinson's disease, there are currently no therapies that slow down disease progression. We aimed to investigate the clinical efficacy of the broadly acting peripheral immunosuppressant drug azathioprine for patients with early Parkinson's disease. METHODS: We did a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial at a single site (the Parkinson's Disease Research Clinic) in Cambridge, UK. Eligible participants were aged 50-80 years and were within 3 years of Parkinson's disease diagnosis (as per UK Parkinson's Disease Society Brain Bank Diagnostic Criteria). Participants were randomly assigned (1:1) using a web-based system to receive daily oral azathioprine 2 mg/kg or placebo for 12 months. The primary outcome was change from baseline Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) gait-axial score in the off-state at 12 months, assessed in the intention-to-treat population, which included all randomly assigned patients who completed the baseline visit. Safety was assessed in all participants who were screened for eligibility. Mixed model repeated measures analysis was used to assess treatment effects. This study was registered with ISRCTN, 14616801, and EudraCT, 2018-003089-14. FINDINGS: Between May 13, 2021, and July 28, 2022, 78 participants were screened, of whom 66 were randomly assigned to azathioprine (n=32) or placebo (n=34), and included in the intention-to-treat analysis. 23 (35%) of 66 patients were female and 43 (65%) were male. At 12 months, the mean change in MDS-UPDRS gait-axial score was 0·54 points (SD 2·43) in the azathioprine group and 0·13 points (2·09) in the placebo group (effect size 0·438 [95% CI -0·694 to 1·57]; p=0·78). 159 adverse events were reported in the azathioprine group and 156 in the placebo group. Eight participants had a serious adverse event in the azathioprine group (24%) and four patients in the placebo group (12%). The most common adverse events in both groups were infections (20 [61%] of 33 participants in the azathioprine group vs 26 [76%] of 34 participants in the placebo group) and gastrointestinal disorders (19 [58%] participants vs 17 [50%] participants). INTERPRETATION: Azathioprine was well-tolerated in this population; however, the primary outcome was not met. Exploratory analyses suggested effects of azathioprine on peripheral and central immune biomarkers and on motor symptoms. Potential clinical effects could be greater in females than males, warranting further exploration. FUNDING: Cambridge Centre for Parkinson-Plus, Cure Parkinson's, National Institute for Health Research Biomedical Research Centre.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Greenland JC, Dresser K, Cutting E, et al. Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Neurol. 2026. PMID: 41389828. doi:10.1016/S1474-4422(25)00386-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。